SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Our findings demonstrated that SGLT2 inhibition was significantly associated with a reduced risk of liver fibrosis and that empagliflozin ameliorated weight gain, hepatic lipid accumulation, histological injury, lipogenesis, oxidative stress, and the expression of inflammatory and fibrosis-related genes in NAFLD mice.